Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285428 · ClinicalTrials.gov registry record · Phase 1
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 3
- Study locations
NCT00285428 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Gilead Sciences. The registered enrollment target is 82 participants, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (63% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00285428, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Conditions Studied
Interventions
- DRUG hA20-humanized anti-CD20 antibody
Study Locations (3)
New York
- New York Presbyterian Hospital/Cornell Medical Center - New York
Pennsylvania
- University Hospital of Pennsylvania - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00285428
The ClinicalTrials.gov registry entry for NCT00285428 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (63% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which hA20-humanized anti-CD20 antibody is the first listed.
NCT00285428 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00285428 about?
NCT00285428 is a clinical study titled "Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma". This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
What is the current status of trial NCT00285428?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2004-09. Estimated completion is 2007-10.
What conditions does trial NCT00285428 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00285428?
The interventions under investigation include: hA20-humanized anti-CD20 antibody (DRUG).
Who is sponsoring clinical trial NCT00285428?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00285428 being conducted?
This trial has 3 study locations across New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.